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A B S T R A C T
Background: Knowledge on the comparative effectiveness of pharmacological treatments to prevent suicide
mortality in bipolar disorder is still lacking.
Methods: We studied the risk of suicide mortality during 1996–2012 among all patients who had been hospi-
talized due to bipolar disorder in Finland (n = 18,018; mean follow-up time 7.2 years) using nation-wide
databases. We used a Cox proportional hazards model. Analyses were adjusted for the effects of time since
diagnosis, order of treatments, current use of other treatments, polypharmacy, number of suicidal hospitaliza-
tions within 2 year (indicator of inherent risk of relapse), age at index date, sex, and calendar year of index date.
In secondary analysis, the first 30 days were omitted from analysis after initiation of a psychopharmacological
treatment to control for protopathic bias.
Results: In comparison between use and no use among specific agents, only lithium (HR 0.33, 95%CI 0.24-0.47,
p<0.0001) and valproic acid (HR 0.61, 95%CI 0.48-0.79, p=0.0002) were associated with a significantly de-
creased risk of suicide in bipolar disorder. Lithium showed a 42% lower risk for suicide mortality compared to
valproic acid (HR 0.58, 95% CI 0.39–0.86, p = 0.007). Hypnotics were associated with a significantly (HR 1.52,
95%CI 1.22-1.90, p=0.0002) higher risk of suicide.
Limitations: Only hospitalized patients were included.
Conclusions: Lithium should be considered as treatment of choice for patients with bipolar disorder who are at
high risk for suicide. Hypnotic use among suicidal patients indicates need for close monitoring of these patients.
1. Introduction
Bipolar disorder is a serious mental disorder that affects around
2–5% of the general population (Clemente et al., 2015, Angst, 1998,
Akiskal et al., 2000). On average, patients with bipolar disorder die
approximately 9 years earlier than the general population and 9 - 15%
of them die by suicide (Crump et al., 2013, Medici et al., 2015,
Hayes et al., 2015).
Lithium salts have been the cornerstone of treatment for bipolar
disorder during the last decades (Collins and McFarland, 2008). How-
ever, in recent years, the usage of other psychotropics has substantially
increased (Vieta et al., 2013, Kessing et al., 2016, Karanti et al., 2016,
Rhee et al., 2020) on the expense of lithium. In particular, antic-
onvulsant drugs like valproic acid and antipsychotics have partially
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replaced lithium as the first-line treatment for this disorder. Other
pharmacological options are also often prescribed as a long-term ad-
juvant therapy or to control some of the symptoms sporadically present
in these patients (Vieta et al., 2018). For instance, in a recent Swedish
nationwide registry study, a trend towards the decreased use of lithium
and increased use of antidepressants was observed in the treatment of
bipolar disorder (Carlborg et al., 2015).
As suicide constitutes the second most frequent cause of death after
cardiovascular disease and is one of the main causes for the premature
mortality observed in patients with bipolar disorder (Ösby et al., 2001),
it should be one of the key aspects considered when choosing treatment
regimens. Many studies have shown lithium to be an effective treatment
for suicidality in bipolar disorder (Kessing et al., 2005, Smith and
Cipriani, 2017, Cipriani et al., 2005, Cipriani et al., 2013, Tondo and
Baldessarini, 2000, Tondo et al., 2001). However, lithium use harbors a
risk for adverse side-effects and discontinuation rates are high, with
adverse effects being the most prominent reason for discontinuation
(Öhlund et al., 2018). Other mood stabilizers have been shown to be
effective as well, but the comparative effectiveness of these treatments
remains conflicting (Søndergård et al., 2008, Smith et al., 2009,
Song et al., 2017, Ferrer et al., 2014, Collins and McFarland, 2008,
Geddes et al., 2010, Oquendo et al., 2011). Also, a large body of the
evidence relies on randomized controlled trials and their meta-analyses,
from which suicidal patients are often excluded (Baldessarini et al.,
2019). Further, studies looking at the comparative effectiveness of
different pharmacological groups, such as mood stabilizers, anti-
psychotics and antidepressants, are scarce (Tondo and
Baldessarini, 2018, Marangell et al., 2008), and a recent publication by
the International Society for Bipolar Disorders Task Force on Suicide in
Bipolar Disorder called for more research on this topic (Schaffer et al.,
2015). Due to lack of data on comparative effectiveness, it is possible
that medication decisions drift towards choosing medication ap-
proaches based on lesser side-effects rather than greater efficacy or anti-
suicidal properties. It has also been postulated that some medications,
such as antidepressants, might increase hypomanic and manic symp-
toms (Viktorin et al., 2014, Pacchiarotti et al., 2013), which may lead to
increased risk of suicide, although data on this topic are still very
conflicting. Moreover, in view of the fact that the number of prescrip-
tions for antidepressants has risen, and a portion of patients with bi-
polar disorder are treated with antidepressants as a monotherapy
(Viktorin et al., 2014), which is considered poor practice at least in
bipolar I disorder (Vieta, 2014), especially the effect of different anti-
depressants on suicide mortality also warrants further study.
It is imperative that robust and current information is available on
both the efficacy and tolerability of medications. The aim of the present
study is to analyze how the use of psychotropic medications is asso-
ciated with deaths due to suicide in patients hospitalized at least once
due to bipolar disorder in Finland. We set out to calculate risk asso-
ciations for all of the most widely used medication groups, including
mood stabilizers, antipsychotics, antidepressants, anxiolytics and hyp-
notics. To our knowledge, this is one of the largest and most compre-
hensive observational study on medication risk for bipolar suicide
mortality to date.
2. Methods
2.1. Study design and data acquisition
Finnish nationwide registries were used to combine prospectively
collected data in order to conduct a population-based cohort study of
patients hospitalized due to (any type of) bipolar disorder. The registers
were used to identify the study cohort (patients hospitalized due to
bipolar disorder between the years 1987 and 2012), to determine the
incidences, durations, and reasons for re-hospitalizations, to obtain
information on reimbursed medications dispensed from pharmacies (all
psychotropic medications except small packages of anxiolytics were
reimbursed in this indication), and to retrieve information on deaths. In
Finland, a forensic autopsy is performed whenever someone is found
dead, and 1) the death is not known to have been caused by an existing
disease or the deceased has not received medical care during his latest
course of disease, 2) there is reason to suspect the death might have
been caused by an accident, suicide, crime, poisoning, vocational dis-
ease, or medical treatment, and 3) the death has been otherwise sudden
or unexpected. Therefore, there is reason to assume that most of the
deaths by suicide are rightly classified as such.
The Prescription, Hospital Discharge and Causes of death registers
and their usage have been described in more detail in our previous
pharmacoepidemiological and methodological studies
(Tanskanen et al., 2017, Tanskanen et al., 2015, Taipale et al., 2016,
Tiihonen et al., 2017). Hospital treatments, deaths, and prescription
fillings are documented in these nationwide registries. In Finland, every
individual has a unique identification code, which makes it possible to
track them even if they would change their name or location of re-
sidence.
The current study included every subject (n = 18,018) hospitalized
at least once with a bipolar disorder diagnosis (ICD-10 diagnoses F30-
31 were used from 1996 onward and Finnish ICD-9 diagnoses 2962-
2964 and 2967A between 1987-1995, the Finnish ICD-9 coding system
somewhat differs from the international one, please see https://www.
julkari.fi/bitstream/handle/10024/131850/Tautiluokitus_ICD9_1987.
pdf for further details) between January 1:st, 1987 and December 31:st,
2012, who had not been diagnosed with broadly defined schizophrenia
during this time period (ICD 10: F20–29, ICD 9: 295, 2971A, 2973A,
2988A, 2989X, 3012C) and who were still alive at the start of the ob-
servation period. A total of 25,860 subjects were initially identified, but
7,758 were excluded due to having a schizophrenia diagnosis as de-
scribed above, 77 excluded due to death before start of observation/
follow-up period, and 7 excluded due to not having any follow-up time
(cohort entry at the end of the observation period). Follow-up data for
hospitalization periods lasting over 30.5 days was censored.
In order to account for survival bias (selective mortality due to
treatment history), we also formed and analyzed a sub-cohort of the
study subjects who 1) had never been hospitalized with any mental
disorder before cohort entry and 2) had not used psychotropic medi-
cation one year prior to cohort entry, namely incident cohort
(n = 2,074). These study subjects could be regarded as first-episode
patients.
Cohort entry date was set as January 1:st, 1996 for subjects hospi-
talized due to bipolar disorder between January 1st 1987 to December
31st 1995, and as the first hospital discharge date for subjects hospi-
talized for the first time on January 1st 1996 or later. The cohorts are
described in detail in Table 1.
2.2. Exposure
The PRE2DUP method was used to define exposure (use) and non-
exposure (non-use) periods for medications (Tanskanen et al., 2017,
Tanskanen et al., 2015, Taipale et al., 2016, Tiihonen et al., 2017).
PRE2DUP calculates current dose with a sliding average, uses package
information such as number of tablets and administration intervals for
injections, and takes into account stockpiling when constructing time
periods of continuous use. Our previous publications on the validation
of the method indicate that PRE2DUP is the most precise method cur-
rently available to estimate drug use, and it gives highly accurate drug
use periods for most drug classes, especially those meant for long-term
use (Tanskanen et al., 2017, Tanskanen et al., 2015, Taipale et al.,
2016), As variation in dose is allowed within the method, no artificial
grace periods are used. Thus, PRE2DUP models actual medication use
on a day-to-day basis. Times when individuals are using a medication
(eg. Lithium) or medication group (eg. Mood stabilizers) are compared
against times when individuals are not using that same medication
(Lithium) or medication group (Mood stabilizers), depending on
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whether analysis is done on medication or medication group level.
Polypharmacy is defined as concurrent use of two or more medications
from the same medication group. As not recorded in the register-based
data as such, periods of cross-titration and actual polypharmacy (with
two or more medications used concomitantly) include somewhat more
uncertainty.
Antipsychotics were defined as ATC code N05A, except for
N05AN01 (lithium), antidepressants as N06A, mood stabilizers as
N03AF, N03AG, N03AX and N05AN01 (lithium), anxiolytics as N05BA,
and finally hypnotics as N05C.
2.3. Outcome
Suicidal deaths were defined with ICD-10 diagnostic codes X60-X84,
as registered in the data from the Causes of death register. Any suicide
occurring within 30 days of a start of a hospitalization were censored.
2.4. Statistical analysis
An analysis of medication use versus suicide mortality was con-
ducted on both cohorts (main cohort and incident cohort) using the Cox
proportional hazards analysis to calculate hazard ratios (HRs) with 95%
confidence intervals (CIs) for use versus non-use of each psychotropic
treatment group. The same analysis was done for individual therapeutic
agents inside the mood stabilizer, and antidepressant groups. A head-to-
head comparison was also completed comparing all mood stabilizers
individually against the most widely used mood stabilizer valproate.
Omission of the first 30 days from analysis after any initiation of a new
psychopharmacological treatment was used to control for protopathic
bias on an additional group level analysis. Analyses were adjusted for
the effects of time since diagnosis, order of treatments, current use of
other treatments, polypharmacy, number of suicidal hospitalizations
within a 2-year time period (indicator of inherent risk of relapse), age at
index date, sex, and calendar year of index date. The p-values were
corrected for multiple comparisons using the Benjamini-Hochberg false
discovery rate (FDR) method. Corrected p-values < 0.05 were con-
sidered statistically significant. Nominal p-values are displayed
throughout the manuscript, unless otherwise stated.
2.5. Ethical considerations
The research project was approved by the Ethics Committee of the
Finnish National Institute for Health and Welfare (dated December 4,
2013, 8/2013). Further permissions were granted by pertinent institu-
tional authorities at the Finnish National Institute for Health and
Welfare (permission THL/1466/6.02.00/2013), The Social Insurance
Institution of Finland (34/522/2013), and Statistics Finland (TK53-
305-13).
Table 1
Characteristics of study cohorts.
Covariates Patient counts (n, %)
Total cohort Incident cohort
Gender
female 9558 (53.05%) 963 (46.43%)
male 8460 (46.95%) 1111 (53.57%)
Age in years at cohort entry date
<30 3345 (18.56%) 588 (28.35%)
30-49 7121 (39.52%) 689 (33.22%)
50-69 5577 (30.95%) 534 (25.75%)
≥70 1975 (10.96%) 263 (12.68%)
Calender year of cohort entry date (n, %)
1996-1999 5107 (28.34%) 343 (16.54%)
2000-2003 3102 (17.22%) 501 (24.16%)
2004-2007 4280 (23.75%) 573 (27.63%)
2008-2012 5529 (30.69%) 657 (31.68%)
Patients remaining in cohort after censoring hospitalizations longer than 30.5 days
no 105 (0.58%) 13 (0.63%)
yes 17913 (99.42%) 2061 (99.37%)
Time in years since diagnosis at CED
0-5 16531 (91.75%) 2074 (100%)
5-10 1472 (8.17%) 0 (0.00%)
>10 15 (0.08%) 0 (0.00%)
Time in years since diagnosis at end of follow-up
0-5 7120 (39.52%) 870 (41.95%)
5-10 5357 (29.73%) 669 (32.26%)
>10 5541 (30.75%) 535 (25.80%)
Use of anxiolytics during follow-up
no 8580 (47.62%) 1466 (70.68%)
yes 9438 (52.38%) 608 (29.32%)
Use of hypnotics during follow-up
no 8069 (44.78%) 1306 (62.97%)
yes 9949 (55.22%) 768 (37.03%)
Use of mood stabilizers during follow-up
no 4749 (26.36%) 827 (39.87%)
yes 13269 (73.64%) 1247 (60.13%)
Use of antidepressants during follow-up
no 4832 (26.82%) 1182 (56.99&)
yes 13186 (73.18%) 892 (43.01%)
Use of antipsychotics follow-up
no 3413 (18.94%) 603 (29.07%
yes 14605 (81.06%) 1471 (70.93%)
Total 18018 (100%) 2074 (100%)
Legend: Characteristics of the study cohorts. Numbers (percentages in parentheses) displayed for both the Total and Incident cohort. CED = cohort entry date.
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3. Results
The total cohort population consisted of 18,018 individuals that
cumulated 129,740 person-years of follow-up. These individuals had a
diagnosis of bipolar disorder, no previous diagnosis of schizophrenia,
were alive at cohort entry date (CED) and their CED was before
31.12.2012. The mean follow-up time for the cohort was 7.2 years.
During the follow-up, 477 suicide events were recorded. The incident
cohort consisted of 2,074 individuals, for whom 32 suicides were re-
gistered during the whole follow-up time (14,040 person years). These
data are shown in Table 1.
Risk associations for completed suicide with different pharma-
cotherapies are presented in Fig. 1. Amount of users per medication
used during follow-up (not censoring 30 days after the beginning of a
hospitalization) is shown in Supplementary Table 1. Of all the psy-
chotropic medications, use of lithium was associated with the lowest
and use of valproic acid with second lowest risk of suicide mortality
(lithium: HR 0.33, 95% CI 0.24 to 0.47, p < 0.001 and valproic acid:
HR 0.61, 95% 0.48 to 0.79, p < 0.001). Results for other mood stabi-
lizers and antipsychotics (data not shown) were not statistically sig-
nificant. No risk associations for the incident cohort reached statisti-
cally significant thresholds, but the rank order was similar to the total
cohort. Incident cohort results are reported in Supplementary Table 2.
Although in general, antidepressant treatment had a non-significant
(after FDR-correction) increase in risk for suicide mortality in com-
parison to non-use of antidepressants (HR 1.28, 95% CI 1.02 to 1.61,
p = 0.03, FDR corrected p = 0.133), the association for risk of suicide
increased and turned significant as the number of times an anti-
depressant regimen had been previously prescribed increased.
Compared to persons who had received none or were on their first
antidepressant treatment, persons who were on their second anti-
depressant treatment had more than 2-fold increased risk of completed
suicide (HR 2.17, 95% CI 1.69 to 2.79, p < 0.001) and the ones with at
least two prior treatments had more than 3-fold higher risk (HR 3.31,
95% CI 2.52 to 4.34, p < 0.0001).
The individual antidepressants associated with the highest suicide
mortality risk were moclobemide (HR 2.25, 95% CI 1.24 - 4.09, p <
0.008) and mirtazapine (HR 1.57, 95% CI 1.13 to 2.19, p < 0.008). The
risk associations for other antidepressants did not reach statistical sig-
nificance when corrected for multiple comparisons.
Use of hypnotics was associated with a significantly increased risk of
suicide (HR 1.52, 95% CI 1.22 to 1.90, p = 0.0002). Hazard ratios for
use of anxiolytics were higher than for non-use, but did not reach sta-
tistical significance (HR 1.21, 95% CI 0.97 to 1.51, p < 0.1). No data on
individual hypnotics or anxiolytics was available for analysis.
In order to control for protopathic bias, the groupwise effects of
treatments were reanalyzed by omitting all periods within the first 30
days after initiation of a new treatment (Table 2). The results for this
analysis were in line with the original analyses, in regard to use of mood
stabilizers still being associated with a significantly lower risk (56%) of
suicide mortality (HR 0.44, 95 CI 0.34 to 0.56, p < 0.0001) and use of
hypnotics with a significantly higher (61%) risk of suicide mortality
(HR 1.61, 95% CI 1.24 to 2.09, p < 0.0004).
Mood stabilizers as a group were associated with the lowest risk for
suicide mortality, so use of specific mood stabilizers were compared
against the use of valproic acid as a reference (Table 3). The hazard
ratio for suicide mortality was 42% lower for lithium (HR 0.58, 95% CI
Figure 1. Suicide mortality analysis.
Legend: Hazard ratios, 95% confidence
intervals, nominal p-values and
Benjamini-Hochberg false discovery
rate (FDR) corrected p-values for risk of
suicide mortality for use vs. non-use of
different medications. P-values still
significant after correction for multiple
comparisons at p < 0.05 level are
marked with an *.
Table 2
Group level suicide mortality analysis, corrected for protopathic bias.
Covariates HR estimate Confidence interval p-value
anxiolytics 1.19 (0.92 - 1.55) 0.19
hypnotics 1.61 (1.24 - 2.09) 0.0003*
mood stabilizers 0.44 (0.34 - 0.56) <0.0001*
antidepressants 1.13 (0.87 - 1.46) 0.36
antipsychotics 1.17 (0.90 - 1.52) 0.24
Legend: Analysis to correct for protopathic bias, in which the first 30 days after
initiation of any new treatment were omitted from the analysis. The table shows
hazard ratios, 95% confidence intervals and nominal p-values for the risk of
suicide mortality when using different medication groups versus not using the
same medication group. P-values still significant after FDR correction for
multiple comparisons at p < 0.05 level are marked with an *.
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0.39 to 0.86, p < 0.007), 59% lower for poly use of mood stabilizers
(HR 0.41, 95% CI 0.24 to 0.69, p < 0.001) and 65% higher for no use of
mood stabilizers (HR 1.65, 95% CI 1.27 to 2.15, p < 0.00018) as
compared to use of valproic acid. Results for other mood stabilizers did
not reach statistical significance.
Some demographic factors were also associated with suicide risk
(Table 4). Our study corroborated also for bipolar patients the general
finding (Hansson et al., 2018) that male sex is associated with a sig-
nificantly increased risk of suicide mortality (HR 2.08, 95% CI 1.73 to
2.52, p < 0.0001). We also replicated the previous findings that ger-
iatric patients (age > 70) had a lower risk of suicide (HR 0.22, 95% CI
0.12 to 0.41, p < 0.001). Time elapsed from initial diagnosis of bipolar
disorder seemed to trend with a decreased risk of suicide mortality,
although these results did not reach statistical significance (when 0 - 5
years elapsed from initial diagnosis was used as the reference point, 5 -
10 years elapsed from initial diagnosis was associated with a 24% re-
duction in risk and > 10 years from initial diagnosis with a 35% re-
duction in risk of committing suicide).
4. Discusson
This observational study suggests that use of lithium or valproic acid
is associated with the lowest risk of suicide mortality in this group of
Finnish patients hospitalized at least once for bipolar disorder, in-
dicating that they are the most effective medications in preventing the
worst outcome in bipolar disorder, suicide. These results are in ac-
cordance with previous studies (Tondo et al., 2001, Tondo and
Baldessarini, 2000, Lauterbach et al., 2008). For example, a systematic
review and meta-analysis of 48 randomized trials (n = 6,674), al-
though three times smaller than the current study in population, re-
vealed that lithium was much more effective than placebo in reducing
completed suicides in mood disorders (odds ratio 0.13, 95% CI 0.03 to
0.66) (Cipriani et al., 2013).
Secondly, although there is a long standing body of evidence in-
dicating that lithium has specific anti-suicidal properties, there are still
insufficient large sample studies analyzing and comparing lithium with
newer treatments like anticonvulsants and antipsychotics in preventing
mortality due to suicide (Schaffer et al., 2015), although the existing
studies so far seem to largely be in favor of lithium (Cipriani et al.,
2013, Søndergård et al., 2008). The randomized trial “BALANCE”
(n = 330) analyzed valproate and lithium both in monotherapy and in
combination for relapse prevention in bipolar I disorder (Geddes et al.,
2010). The results of that trial showed that lithium and valproate
combination and lithium monotherapy seemed to be better than
valproate monotherapy. Another double-blind clinical trial (n = 98)
analyzed suicide events and attempts between lithium and valproate
users in a sample of high-risk suicide attempters with bipolar disorder,
but did not find any differences in effectiveness between the medica-
tions (Oquendo et al., 2011). However, yet another study with 12,662
Oregon Medicaid patients diagnosed with bipolar disorder showed a
higher ratio of suicide attempts with the use of valproate than with
lithium, but not in terms of completed suicides (Collins and
McFarland, 2008). In the current study, use of lithium was associated
with a markedly lower risk for suicide than use of valproic acid, when
compared against each other. Nevertheless, both valproic acid and li-
thium were associated with a markedly decreased risk for suicide. Al-
though lithium was more effective, valproic acid is considered to have
some advantages over lithium, as it is often better tolerated, can be
prescribed in a loading-dose strategy and might thus overall have a
broader scope in the treatment of bipolar disorder. In general, use of
any mood stabilizer (as a groupwise effect) was associated with a re-
duced risk of committing suicide. This result does likely not stem from
mere confounding, as no such positive association was observed for use
of antipsychotics, which like mood stabilizers, are also often reserved
for the more seriously ill patients.
The usage of antidepressants in bipolar disorder has been sub-
stantially under-studied, especially in comparison to their use in uni-
polar depression (Vieta and Garriga, 2016). Our results show that use of
certain antidepressants might in some cases be associated with an in-
creased risk for suicide mortality in patients hospitalized at least once
for bipolar disorder, which is in accordance with previous studies
(Kessing et al., 2005, McElroy et al., 2006). For instance, in another
observational study, a very similar association was found between
suicidal behavior and previous antidepressant trials in patients with
bipolar disorder (OR 1.29, p = 0.02) (Undurraga et al., 2012). Also, a
study by Kessing et al showed a robust increase in suicide rate (Risk
ratio 6.07) in bipolar patients who had purchased antidepressants vs.
those who had not (Kessing et al., 2005). By contrast, a large body of
research about antidepressants has demonstrated them to be a protec-
tive factor in unipolar depression or in the general population for both
suicidal behavior and mortality (Reseland et al., 2006), especially after
starting to favor the use of selective serotonin re-uptake inhibitors
(SSRIs) instead of the more toxic tricyclic antidepressants (TCAs)
(Bramness et al., 2007). For example, it was found that suicide rates
declined by 13.5% in the United States from 1985 to 1999, when at the
same time antidepressant prescriptions increased over 4-fold, mostly
due to SSRIs prescription. The study reported that both prescription
rates of SSRIs and other second-generation antidepressants were
Table 3
Head-to-head comparison of mood stabilizers.
Covariates HR estimate Confidence interval p-value
valproic acid reference reference reference
lithium 0.58 (0.39 - 0.86) 0.00651*
lamotrigine 1.55 (1.05 - 2.29) 0.02716
carbamazepine 1.25 (0.76 - 2.07) 0.38366
oxcarbazepine 1.10 (0.35 - 3.51) 0.87040
gabapentin 2.85 (0.89 - 9.10) 0.07764
topiramate 1.03 (0.14 - 7.44) 0.97790
poly use of mood stabilizers 0.41 (0.24 - 0.69) 0.00095*
no use of mood stabilizer 1.65 (1.27 - 2.15) 0.00018*
Legend: Hazard ratios, 95% confidence intervals and p-values for risk of suicide
mortality for different mood stabilizers as compared to use of valproic acid. No
use of mood stabilizer refers to times when a person is not using a mood sta-
bilizer, use of any other medication is allowed. Nominal p-values are displayed.
P-values still significant after FDR correction for multiple comparisons at p <
0.05 level are marked with an *.
Table 4
Analysis of sex, age at CED, calender year of CED and time since diagnosis in the
association between suicide mortality and antidepressant treatment in bipolar
disorder.
Covariates HR (95% CI) p value
Sex
female reference reference
male 1.95 (1.62 to 2.36) < 0.0001*
Age at CED
< 30 reference reference
30 - 49 0.92 (0.70 to 1.21) 0.56492
50 - 69 1.00 (0.75 to 1.33) 0.98603
≥ 70 0.30 (0.15 to 0.55) 0.00012*
Calendar year of CED
1996 - 1999 reference reference
2000 - 2003 0.73 (0.57 to 0.94) 0.01549
2004 - 2007 0.48 (0.36 to 0.64) < 0.0001*
2008 - 2012 0.52 (0.38 to 0.72) < 0.0001*
Time since diagnosis (years)
0 - 5 reference reference
5 - 10 0.76 (0.53 to 1.10) 0.14644
> 10 0.65 (0.37 to 1.15) 0.13868
Legend: Hazard ratios, 95% confidence intervals and p-values for risk of suicide
mortality. CED = Cohort entry date. P-values still significant after FDR cor-
rection for multiple comparisons at p < 0.05 level are marked with an *.
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significantly inversely associated with suicide rates (Grunebaum et al.,
2004). As antidepressant use in general was not significantly associated
with increased risk of suicide (when corrected for multiple compar-
isons) in our study, it would seem likely that the observed increase in
risk as the number of antidepressant treatments increased is skewedness
caused by confounding by indication. The individuals with a larger
number of antidepressant treatment attempts are likely patients more
often relapsing into depression or not benefitting from the first or
second antidepressant treatment attempt, and thus in general at a
greater risk for suicide.
A previous Swedish study analyzed patients with bipolar disorder
who started an antidepressant treatment and had not had anti-
depressant treatment during the previous year (n = 3,240). The main
results were that a great percentage of the patients (35%) were treated
with antidepressant monotherapy and that antidepressant monotherapy
was associated with an increased risk of treatment-emergent mania (HR
2.83, 95% CI 1.12 to 7.19) (Viktorin et al., 2014). In addition to this, in
that same study, it was shown that there was no risk of mania when
patients received an antidepressant and a mood stabilizer (lithium,
valproate or lamotrigine) at the same time. This prevention of treat-
ment emergent mania could account for part the of association of
lowered risk of suicide observed in our study for patients using mood
stabilizers such as lithium and valproic acid, although at least lithium
has been shown to reduce the risk of suicide both in bipolar and uni-
polar patients by itself (Cipriani et al., 2005).
The high association between moclobemide and suicides might at
least in part be explained by confounding, as this drug is sometimes
prescribed to patients after non-adherence to other psychotropics, due
it being considered to have lesser side-effects than other MAO-A in-
hibitors, or being prescribed to patients after several failed attempts
with other antidepressants. On the other hand, moclobemide is some-
times also considered to be one the least effective of the antidepressants
in treating depression, as was also the case in our previous study esti-
mating the real-world effectiveness of antidepressants in preventing
hospitalization in major unipolar depression patients, where moclobe-
mide had the highest hazard ratio for re-hospitalization (Tiihonen et al.,
2017). Thus, the increased hazard ratio observed for moclobemide
could in part also be due to its ineffectiveness in treating depressive
symptoms.
Finally, mood stabilizers, especially lithium and valproic acid seem
to be associated with a markedly reduced risk of suicide in bipolar
disorder. Despite of this, antidepressants are still widely prescribed as
monotherapy to treat bipolar disorder, even for young patients, who are
considered to be at a high risk for suicide due to their young age and
close temporal proximity to the onset of the disorder (Post et al., 2003,
Simon et al., 2004, Shi et al., 2004). This is somewhat understandable
given the fact that especially lithium may cause unwanted side-effects
for some patients and requires active monitoring and follow-ups.
However, our study implies that this antidepressant monotherapy trend
might lead to increased suicide rates in bipolar patients and should be
more extensively studied, before this treatment regime is further com-
mitted to. Further, because suicide risk in bipolar disorder is high at
onset of disease and especially for young patients, this group of patients
might actually benefit most from the lower risk of suicide mortality
associated with use of lithium or valproic acid (Vieta et al., 2018). In
our study, use of hypnotics was also associated with an increased risk of
suicide. Although the result may be due to residual confounding, it is in
line with a previous study by Kessing et al. (Kessing et al., 2005). As
these drugs along with anxiolytics might inhibit impulse control, pos-
sibly even after their hypnotic effect wears off, they might lead to in-
creased translation from suicidal ideations to suicidal behaviors
(Dodds, 2017, Sun et al., 2016). Patients at high risk for suicide using
these medications should therefore be closely monitored.
4.1. Limitations
Our study only involved individuals who have been hospitalized due
to bipolar disorder. As such, patients with a milder course of illness,
such as some type II bipolar patients might not be well represented in
this sample. However, the Finnish national registries are very com-
prehensive and it is likely that we have caught nigh all of the patients
hospitalized due to bipolar disorder in Finland. The universal health-
care and high quality of psychiatric care provided also increases the
likelihood that schizophrenia spectrum disorders were comprehensively
excluded from the sample. We did not analyze the effect of other psy-
chiatric comorbidities, such as substance abuse disorders, anxiety dis-
orders or personality disorders in this study, which is a marked lim-
itation. It must be noted that it is possible that some or all of the
association with increased risk observed in the current study could be
due to confounding by indication or protopathic bias, as our analysis for
protopathic bias would suggest. Hence, further studies are warranted,
and rather than pointing at an increased risk of suicide due to the effect
of antidepressant medications, our results could be interpreted in the
sense that the patients who received antidepressants were those who
were at highest risk of suicide (medication initiated due to greater
depressive symptom severity). As suicide is a one-time event, within-
individual analyses capable of correcting for this sort of confounding by
indication could not be performed. However, as this result remains
somewhat unclear, this study does warrant for closer clinical mon-
itoring of bipolar patients using antidepressants and at an otherwise
high risk for suicide.
5. Conclusions
According to our data, use of mood stabilizers, primarily lithium,
but also valproic acid were associated with a markedly lower risk of
dying by suicide among patients with bipolar disorder. Use of hypnotics
in general was associated with an increased risk of suicide.
To conclude, clinicians should continue prescribing lithium or val-
proic acid to suitable bipolar patients at high risk for suicide with risk
factors including but not limited to close proximity to onset of disorder,
previous suicide attempts, younger age, comorbid anxiety disorders,
relatives with bipolar disorder and previous manic or hypomanic epi-
sodes. Lithium should be the primary choice, but valproic acid might be
suitable for situations in which quick loading-doses are required or side-
effects are a major concern, such as for the very young and the elderly.
Use of hypnotics in patients at an increased risk for suicide should
trigger the need for closer monitoring for suicidal signals.
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